Treos Bio Announces Presentation of Final Results from Phase 1b Study of PolyPEPI1018 Immunotherapy for Late-Stage Metastatic Colorectal Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
05 juin 2023 09h00 HE
|
Treos Bio Limited
LONDON, June 05, 2023 (GLOBE NEWSWIRE) -- Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide...
Treos Bio Announces First Patient Dosed in Phase 2 Trial of PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor for the Treatment of Metastatic Colorectal Cancer
27 juin 2022 07h00 HE
|
Treos Bio Limited
LONDON, June 27, 2022 (GLOBE NEWSWIRE) -- Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide...
Treos Bio Announces First Patient Dosed in Phase 1b Trial of PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer
07 févr. 2022 07h00 HE
|
Treos Bio Limited
LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide...
Treos Bio Announces FDA Clearance of IND Application for PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer
18 août 2021 07h00 HE
|
Treos Bio Limited
OBERTO 201 Phase 1b trial expected to initiate 3Q 2021 U.S. Department of Defense (“DoD”) Congressionally Directed Medical Research Program will fund the trial, to be conducted in collaboration with...
Treos Bio Enters into Clinical Collaboration to Evaluate its Polypeptide Cancer Immunotherapy PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor
07 juil. 2021 07h00 HE
|
Treos Bio Limited
Company expects to initiate a Phase I/II trial in Q4 2021 LONDON, July 07, 2021 (GLOBE NEWSWIRE) -- Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and...
Treos Bio Announces the Publication of Preclinical Data in Frontiers in Genetics Showing its COVID-19 Peptide Vaccine Mimics the Diversity of T Cell Immunity Produced by Natural SARS-CoV-2 Infection
28 juin 2021 07h00 HE
|
Treos Bio Limited
LONDON, June 28, 2021 (GLOBE NEWSWIRE) -- Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision off-the-shelf and...
Treos Bio Announces the Appointment of Ruti Alon to its Board of Directors
01 juin 2021 16h01 HE
|
Treos Bio Limited
LONDON, June 01, 2021 (GLOBE NEWSWIRE) -- Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision off-the-shelf and...
Treos Bio Announces $14 Million Convertible Loan Note Financing to Advance Platform of Computationally Designed Peptide-Based Cancer Immunotherapies
31 mars 2021 07h00 HE
|
Treos Bio Limited
Proceeds will fund Phase II clinical trials of PolyPEPI-1018, the Company’s off-the-shelf polypeptide immunotherapy for metastatic colorectal cancer Financing was led by Luminous Ventures and the UK...
PepTC Vaccines Publishes Positive Preclinical Results for COVID-19 Peptide Vaccine That Shows Broad T Cell Response
19 oct. 2020 07h15 HE
|
Treos Bio Limited
LONDON, Oct. 19, 2020 (GLOBE NEWSWIRE) -- PepTC Vaccines Limited, a subsidiary of Treos Bio Limited, today announced the publication of positive preclinical results of its investigational...